1. Introduction {#sec1}
===============

Maintenance of well-functioning vascular graft is a major challenge in continuing care of patients who have vascular access for hemodialysis and vascular bypass procedures. Different types of vascular grafts are available for dialysis access settings and peripheral vascular reconstructions [@bib1]. The greater saphenous vein remains the conduit of choice for vascular procedure and native arteriovenous fistula (AVF) is recommended as the first choice of vascular access for hemodialysis [@bib2]. However, autologous vein graft and access are not feasible in a significant number of patients. The use of prosthesis conduit to create a bridging access graft and vascular reconstruction are the best alternative. The expanded polytetrafluoroethylene (PTFE) was the most commonly used vascular prosthesis with limited graft patency and significant number of complications [@bib3]. Biologic prosthesis (BP) has been reported as a safe alternative to polytetrafluoroethylene (PTFE) in vascular reconstruction [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. However, efficacy of BP remains controversial. We, therefore, conducted a systematic review to summarize previous available evidences comparing the BP and PTFE in terms of graft patency.

2. Methods {#sec2}
==========

A literature search of the MEDLINE and Scopus was performed from January 1946 to December 2015. The search strategy is described in [appendix 1](#appsec1){ref-type="sec"}.

2.1. Inclusion criteria {#sec2.1}
-----------------------

Studies were included in the review if they met with the following criteria:-Had study design as randomized controlled trial or cohort study-Studied in adult patients aged 18 years or older-Patients who received vascular access procedure for hemodialysis or femoropopliteal bypass-Compared clinical outcomes between biologic prosthesis (BP), polytetrafluoroethylene (PTFE), and/or autologous veins graft (VG):-Had at least on of following clinical outcomes: graft patency, graft survival, graft thrombosis, graft infection.

The reference lists of all relevant studies were also reviewed. If studies were duplicated reports, the one with the most complete data was chosen. For studies which reported insufficient data, the corresponding authors were contacted and invited to provide more information. Two attempts were made to contact authors and those who did not respond were excluded from the review.

2.2. Outcomes {#sec2.2}
-------------

The outcome of interest was graft patency which was detected by audible Doppler signal or duplex ultrasound. Primary graft patency was analyzed up to the first graft thrombosis while patency following graft revision procedures was used as secondary patency.

2.3. Data extraction {#sec2.3}
--------------------

Two reviewers (CW and BS) independently extracted the data from each study using a standard data extraction form. Information extracted included general data (i.e. author, year of publication, journal), study characteristics (i.e. study design, setting), patient characteristics (i.e. age, underlying diseases, surgical procedures, type of prosthesis, follow up period), and outcome as described above. Any disagreement was discussed and resolved by consensus with the third party (SR).

2.4. Risk of bias assessment {#sec2.4}
----------------------------

The quality of studies was independently assessed by CW, BS, and SH on the basis of representativeness of studied subjects, information bias (i.e., ascertainment of outcome and surgical technique), and confounding bias [@bib15] ([appendix 2](#appsec2){ref-type="sec"}). For the randomized controlled trial (RCT) study, the assessment was done using established tools recommended by the Cochrane library [@bib16]. Each item was graded as "yes" for low risk of bias, "no" for high risk of bias, and "unclear" if there was insufficient information to judge [@bib16]. Any disagreement between the reviewers was discussed and resolved by consensus.

2.5. Statistical analysis {#sec2.5}
-------------------------

Data from RCTs and cohort studies were pooled separately. The risk ratio (RR) of graft patency for each included study was estimated. The heterogeneity of RRs across studies was assessed using Cochran\'s Q test and the degree of heterogeneity was quantified using the I^2^ statistic. If the heterogeneity was significant or I^2^ \> 25%, a random effects model using the Der-Simonian and Laird method was applied for pooling RRs, otherwise the fixed effects model was used.

Meta-regression analysis was used to assess the source of heterogeneity by fitting age, and type of wound in the meta-regression model. Funnel plot with or without contour-enhancement was applied to detect publication bias due to small study effects. Egger\'s test was used for assessing the asymmetry of the funnel plot. All analyses were performed using STATA version 14.0. A P-value \< 0.05 was considered statistically significant, except for the heterogeneity test for which p \< 0.1 was used.

3. Results {#sec3}
==========

3.1. Identifying studies {#sec3.1}
------------------------

A flow diagram of the study selection process is shown in [Fig. 1](#fig1){ref-type="fig"}. The initial literature search identified 183 and 261 studies from PubMed and Scopus databases, respectively. Among these 444 studies, 95 studies were duplicates, leaving 349 studies for title or abstract review. After reviewing, 326 studies were ineligible leaving 23 studies for review full articles. Among 23, 12 studies were not comparative studies, leaving 11 studies with a total of 2627 patients available for extraction and analysis. Agreement for selection of studies and data extractions between the two reviewers were 92·2% ((kappa = 0.92, p \< 0.001) and 93.9% (kappa = 0.93, p \< 0.001) for outcomes. Characteristics of the 11 included studies are described in [Table 1](#tbl1){ref-type="table"} [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. Among them, 4 studies were randomized RCTs [@bib5], [@bib6], [@bib11], [@bib12] whereas 7 studies were cohorts [@bib4], [@bib7], [@bib8], [@bib9], [@bib10], [@bib13], [@bib14]. Most of the studies were from the European **countries**(7/11). Five studies used biologic prosthesis (human umbilical vein and bovine mesenteric vein) while 6 studies used biosynthetic prosthesis [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. Seven studies compared BP with PTFE [@bib4], [@bib7], [@bib8], [@bib9], [@bib10], [@bib13], [@bib14] and 3 studies compared PTFE with VG [@bib4], [@bib7], [@bib10].

3.2. Risk of bias assessment {#sec3.2}
----------------------------

Among 7 cohorts [@bib4], [@bib7], [@bib8], [@bib9], [@bib10], [@bib13], [@bib14], low risk of selection bias from the use of representative cases was found in 4 (57.14%) studies [@bib4], [@bib7], [@bib10], [@bib14]. The ascertainment of all outcomes was clearly described in all studies [@bib4], [@bib7], [@bib8], [@bib9], [@bib10], [@bib13], [@bib14]. The ascertainment of intervention was clear in all studies [@bib4], [@bib7], [@bib8], [@bib9], [@bib10], [@bib13], [@bib14]. Confounding bias was found likely to be present in 4 (57.14%) studies [@bib4], [@bib7], [@bib10], [@bib13].

In the RCT study, all studies [@bib5], [@bib6], [@bib11], [@bib12] had low risk of bias in and selective outcome reports. However, in the domains of blinding and sequence generations, allocation concealments, and address incomplete outcome data 100%, 50%, 25%, and 50% of studies had high risk of bias, respectively. High risk of bias was found in the domains of free of other bias and description of other bias ([Table 2](#tbl2){ref-type="table"}).

3.3. Graft patency {#sec3.3}
------------------

Comparing biologic prosthesis (BP) VS PTFE, pooling was based on 3 RCTs with a sample size of 187 vs 213. The RR was moderately heterogeneous (Chi-square = 4.64 (d.f. = 2) p = 0.098; I^2^ = 56.90%), see [Fig. 2](#fig2){ref-type="fig"}. Pooling with a random-effect model yielded the pooled RR of 1.54 (95% CI: 1.10, 2.16), indicating 54% higher graft patency in BP than PTFE). A sensitivity analysis was performed by adding the 7 cohorts in this pooling which yield similar results with the pooled RR of 1.29 (95% CI: 1.15, 1.45) ([Fig. 3](#fig3){ref-type="fig"}). Neither Egger\'s test nor the funnel plot suggested asymmetry (coefficient = 1.44, SE = 0.64, p = 0.05).

Comparing biologic prosthesis (BP) VS autogenous veins graft (VG), the pooled RR of graft patency for BP vs VG was 0.74 (95% CI, 0.55, 1.00) ([Fig. 4](#fig4){ref-type="fig"}), indicating 26% lower graft patency but not significant in BP than VG. Neither Egger\'s test nor the funnel plot suggested asymmetry (coefficient = 1.11, SE = 1.34, p = 0.56).

4. Discussion {#sec4}
=============

The use of vascular prosthesis is unavoidable in a significant number of patients who need vascular conduit or access for hemodialysis. The ideal prosthetic material for vascular construction with unsuitable superficial vein network remains a matter for debate, as there have been no large prospective, randomized trials; moreover, the materials have been used under different circumstances and the methods for reporting patency have not been uniform [@bib16]. Our first meta-analysis indicated that the biosynthetic prosthesis might be benefit over PTFE by increasing graft patency. Comparing biologic prosthesis (BP) and autogenous veins graft (VG) found that graft patency for BP was 26% lower than VG but not statistically significance.

A number of alternative graft materials are commercial available. The bioprosthesis derived from bovine mesenteric veins, obtained by process of glutaraldehyde cross linking, has been reported longer patency, lower rates of reoperation, and lower incidence of thrombosis [@bib17]. Biosynthetic prosthesis, a glutaraldehyde-tanned ovine collagen-polyester composite, obtained by inserting polyester mesh-covered mandrills beneath the cutaneous trunci muscle of sheep has the advantage of the natural collagen, deprived of its immunogenicity and the polyester net provides increased mechanical resistance to deterioration [@bib18]. Polytetrafluoroethylene (PTFE) is the most popular graft material, despite its higher incidence of graft thrombosis, infection, and seroma formation. Multiple reports have shown PTFE graft to be adequate alternative conduit for vascular reconstruction. Heparin-bonded prosthetic graft which are now widely using with significant results available in literature is an alternative to biologic prosthesis. Systemic review and meta-analysis should be done in this topic.

The strength of our studies is that we analyzed the RCTs that could minimize selection and confounding biases between BP and PTFE. A sensitivity analysis was performed by including comparative cohort studies to confirm the results. However, our results were pooled based on moderate heterogeneity across included studies. The number of included RCTs was also quite small. Additional data can not accessed (other journals e.g. EMBASE, unpublished data). The question asked in this meta-analysis is unable to compare all three grafts, but compares biosynthetic and PTFE and biosynthetic and PTFE and VG in two separate statistical tests. Furthermore, some studies (25--50%) had high risk of bias in sequence generations, allocation concealments, and address incomplete outcome data. Therefore, further large scale RCTs or updated meta-analysis is required to confirm our results.

5. Conclusion {#sec5}
=============

Biosynthetic vascular prostheses are promising alternative graft material when an autologous vein is limited, both for the hemodialysis assess and femoropopliteal bypass. An updated meta-analysis or a large scale randomized control trial is required to confirm this results.
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 {#appsec1}

Search strategy for PubMed and Scopus {#appsec1.1}
-------------------------------------

1.Chronic renal failure2.Peripheral arterial disease3.Arterial stenosis4.Arterial occlusion5.Vascular access6.Femoropopliteal bypass7.Hemodialysis8.Biologic prosthesis9.Polytetrafluoroethylene10.Prosthesis11.Autologous veins graft12.Graft patency13.Graft survival14.Graft thrombosis15.Graft infection16.Graft dysfunction17.(1 or 2 or 3 or 4 or 5 or 6 or 7)18.(8 or 9 or 10 or 11)19.(12 or 13 or 14 or 15 or 16)20.(17 or 19)21.(18 and 20)

Appendix 2. Risk of bias assessment form {#appsec2}
========================================

For Cohort studyAuthorDomainItemLow risk of biasSelection biasRepresentative of cohorts\
A. Consecutive/randomly selected from cases population with extensive inclusion criteria\
B. Spectrum of diseases\
C. Did not mentionInformation biasAscertainment of outcome measurement\
A. Cleary describe definition of outcomes\
B. Did not describeAscertainment of Interventions\
A. No switching of treatment between groups\
B. Not describeConfounding biasConfounding bias\
A. Adjusting confounding factors in analysis\
B. Did not adjust confounding factorsFor RCT studyAuthorAdequate sequence generationAdequate allocation concealmentBlindingAddress incomplete outcome dataSelective outcome reportFree other biasDescription of other bias

![Identification of studies for inclusion from PRISMA guideline.](gr1){#fig1}

![Meta-analysis of graft patency between BP and PTFE.](gr2){#fig2}

![Sensitivity analysis of graft patency between BP and PTFE.](gr3){#fig3}

![Meta-analysis all study of graft patency between BP and VG.](gr4){#fig4}

###### 

Characteristics of comparative studies that had biologic prosthesis.

Table 1

  Authors                     Year   Study design   Number of patients   Procedure                 Autologous veins graft                 Biologic prosthesis   Polytetrafluoroethylene   Country
  --------------------------- ------ -------------- -------------------- ------------------------- -------------------------------------- --------------------- ------------------------- ----------------
  Eikhoff et al. [@bib6]      1983   RCT            104                  Femoro-popliteal bypass   NA[a](#tbl1fna){ref-type="table-fn"}   50                    54                        Denmark
  Eikhoff et al. [@bib5]      1987   RCT            105                  Femoro-popliteal bypass   NA[a](#tbl1fna){ref-type="table-fn"}   50                    55                        Denmark
  Mccollum et al. [@bib11]    1991   RCT            191                  Femoro-popliteal bypass   NA[a](#tbl1fna){ref-type="table-fn"}   87                    104                       United Kingdom
  Enzler et al. [@bib7]       1996   Cohort         429                  Hemodialysis access       301                                    59                    69                        Switzerland
  Koch et al. [@bib10]        1996   Cohort         347                  Femoro-popliteal bypass   63                                     112                   172                       Germany
  Wang et al. [@bib14]        1996   Cohort         109                  Hemodialysis access       NA[a](#tbl1fna){ref-type="table-fn"}   61                    48                        Taiwan
  Bacchini et al. [@bib4]     2001   Cohort         911                  Hemodialysis access       862                                    22                    63                        Italy
  Glickman et al. [@bib8]     2003   Cohort         74                   Hemodialysis access       NA[a](#tbl1fna){ref-type="table-fn"}   59                    15                        USA
  Katzman et al. [@bib9]      2005   Cohort         276                  Hemodialysis access       NA[a](#tbl1fna){ref-type="table-fn"}   183                   93                        USA
  Morosetti et al. [@bib12]   2011   RCT            57                   Hemodialysis access       30                                     27                    NA                        Italy
  Ozpak et al. [@bib13]       2015   Cohort         24                   Axillary bypass           NA[a](#tbl1fna){ref-type="table-fn"}   12                    12                        Turkey

NA = not applicable.

###### 

Quality assessment of the included studies.

Table 2

  Cohort studies                                     
  -------------------------------- ----- ----- ----- -----
  Enzler et al. (1996) [@bib7]     yes   yes   yes   no
  Koch et al. (1996) [@bib10]      yes   yes   yes   no
  Wang et al. (1996) [@bib14]      yes   yes   yes   yes
  Bacchini et al. (2001) [@bib4]   yes   yes   yes   no
  Glickman et al. (2003) [@bib8]   no    yes   yes   yes
  Katzman et al. (2005) [@bib9]    no    yes   yes   yes
  Ozpak et al. (2015) [@bib13]     no    yes   yes   no

  RCT study                                                            
  ---------------------------------- ----- ----- ---- ----- ----- ---- ----
  Eikhoff et al. (1983) [@bib6]      no    yes   no   no    yes   no   no
  Eikhoff et al. (1987) [@bib5]      yes   yes   no   no    yes   no   no
  Mccollum et al. (1991) [@bib11]    yes   yes   no   yes   yes   no   no
  Morosetti et al. (2011) [@bib12]   no    no    no   yes   yes   no   no

Yes = low risk of bias.
